Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Arcutis Biotherapeutics Inc (ARQT)

264 + Investors. Track Smart Money conviction in ARQT. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -14
Streak
1Q ▼
Buyers last Q
51%

Smart Money Signals — ARQT

Based on 265 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their ARQT positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🏔️

At the ownership peak (95% of max)

95% of all-time peak
265 hedge funds hold ARQT right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +12% more funds vs a year ago

fund count last 6Q
+28 new funds entered over the past year (+12% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 51% buying

145 buying140 selling
Last quarter: 145 funds bought or added vs 140 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-35 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 33 → 35 → 75 → 40. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

41% of holders stayed for 2+ years

■ 41% conviction (2yr+) ■ 33% medium ■ 26% new
108 out of 265 hedge funds have held ARQT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares +1%, value -18%

Value
-17%
Shares
+1%
Last quarter: funds added +1% more shares while total portfolio value only changed -18%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
🚀

Acceleration phase — new buyers rushing in

64 → 33 → 35 → 75 → 40 new funds/Q
New funds entering each quarter: 33 → 35 → 75 → 40. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 49% veterans vs 30% newcomers

■ 49% veterans ■ 21% 1-2yr ■ 30% new
Entry-cohort mix of 273 holders: 134 (49%) are 2+ year veterans, 56 entered 1–2 years ago, and 83 (30%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 39% AUM from major funds

39% from top-100 AUM funds
49 of 265 holders rank in the top 100 by AUM, accounting for 39% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.8
out of 10
Low Exit Risk
Exit risk score 3.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ARQT

In 2026 Q1, 145 hedge funds were net buyers of ARQT (40 opened a new position, 105 added to an existing one), while 140 reduced or exited (86 trimmed, 54 sold completely) — a 51% buyer ratio, indicating a slight buying edge. 39% of total institutional value in ARQT is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -14 funds (more exits than new entries). Total institutional holders: 265.

Hedge Fund Ownership: ARQT

How many hedge funds hold ARQT — quarterly history vs. share price
Quarterly hedge fund ownership of ARQT vs. share price

Market Analysis: ARQT

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ARQT

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Arcutis Biotherapeutics Inc (ARQT) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much ARQT has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 46d ago
ARQT
-0.1%
XLV
+5.5%

ARQT outperformed XLV by -5.6% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 1d ago
ARQT
+0.0%
XLV
+0.0%

Since the filing became public, ARQT outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

31 top-rated funds 4 high-conviction
Consensus
6.5
/ 10
breadth
×
Elite
4.2
/ 10
conviction
Hedge Fund Positioning: ARQT
2026 Q2 Stats Unlock in 4 days 264 + Investors

Track Smart Money conviction in ARQT. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 264 278 -5.04%
13F Shares 133M 131M 1.45%
Total Value $3.08B $3.74B -17.6%
New Positions 39 74 -35
Increased Positions 102 105 -3
Closed Positions 53 30 +23
Reduced Positions 85 71 +14
Total Calls 4 5 -20.0%
Total Puts 4 5 -20.0%
PUT/CALL Ratio 1.0 1.0 Neutral

Statistics: ARQT

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

264 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ARQT. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 ARQT holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Pivotal bioVenture Partners Investment Advisor LLC 10.78% 1,265,283 $33.2M
2 Jones Hill Capital LP 6.07% 1,089,701 $28.6M
3 Montanova Capital, LLC 5.96% 12,437,000 $326.1M
4 Frazier Life Sciences Management, L.P. 5.64% 9,874,511 $258.9M
5 Pavaki Capital Management LLC 4.13% 202,000 $5.9M
6 Rubric Capital Management LP 1.99% 8,271,577 $216.9M
7 Privium Fund Management B.V. 1.92% 399,367 $10.5M
8 Patient Square Capital LP 1.50% 370,000 $9.7M
9 Fishman Jay A Ltd/Mi 1.24% 595,005 $15.6M
10 Tejara Capital Ltd 1.22% 113,084 $3.0M
11 Orbimed Advisors LLC 0.99% 2,042,000 $53.5M
12 MYDA Advisors LLC 0.94% 240,000 $6.3M
13 1492 Capital Management LLC 0.90% 116,211 $3.0M
14 Oberweis Asset Management Inc/ 0.74% 1,372,941 $36.0M
15 Lion Point Capital, LP 0.66% 5,250 $138K
16 PFM Health Sciences, LP 0.54% 242,069 $6.3M
17 Essex Investment Management Co LLC 0.47% 137,500 $3.6M
18 Stempoint Capital LP 0.45% 98,945 $2.6M
19 Perpetual Ltd 0.42% 1,109,657 $29.1M
20 Polar Capital Holdings Plc 0.41% 6,606,945 $173.2M
21 Gilder Gagnon Howe & Co LLC 0.36% 1,313,211 $34.4M
22 Virtus Investment Advisers, LLC 0.29% 47,698 $1.3M
23 PSP Research LLC 0.27% 19,700 $517K
24 Yorktown Management & Research Co Inc 0.26% 16,000 $420K
25 MFA Wealth Services 0.25% 16,196 $425K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Arcutis Biotherapeutics Inc (ARQT)

What does the Smart Money Trend signal show for ARQT?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their ARQT positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for ARQT?

Slight buying edge — 51% buying: Last quarter: 145 funds bought or added vs 140 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for ARQT holders?

Strong quality — 39% AUM from major funds: 49 of 265 holders rank in the top 100 by AUM, accounting for 39% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held ARQT?

41% of holders stayed for 2+ years: 108 out of 265 hedge funds have held ARQT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Arcutis Biotherapeutics Inc (ARQT) following the 2026 Q2 hedge fund 13F filings?

As of today, ARQT has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), ARQT has gained -0.1% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →